DelveInsight’s “Tumor-Infiltrating Lymphocytes (TIL) Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Tumor-Infiltrating Lymphocytes market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Tumor-Infiltrating Lymphocytes drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Tumor-Infiltrating Lymphocytes treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Tumor-Infiltrating Lymphocytes (TIL): An Overview
Lymphocytes, or white blood cells, are an important part of the immune system that helps the body fight off infections or eliminate diseased cells. Lymphocytes, made up of T cells and B cells, are constantly patrolling the body to identify cells that shouldn’t be present, including cancer.
As cancers grow, lymphocytes recognize these cells as abnormal and penetrate into the tumor. These are the tumor-infiltrating lymphocytes or TILs. Once in the tumor, the TILs begin working to kill cancer cells. Sometimes, they’re prevented from doing that by brakes in the immune system or signals from the tumor that weakens the immune response. Immune checkpoint inhibitors were developed to block some of those breaks and unleash the immune cells to attack cancer.
The interaction between cancer and immune cells in the tumor microenvironment (TME) is thought to be crucial for the control of the development and progression of malignant tumors. Accordingly, tumor-infiltrating lymphocytes (TILs) have been identified in primary tumor tissue, tumor-bearing lymph nodes, and metastases of numerous cancer types. TILs are defined as lymphocytes within and around cancer cells and have been associated with a survival benefit.
Because TILs come directly from the tumor, they already recognize many targets on the cancer cells. This makes them a very attractive therapy.
Currently, TIL therapies are only available through clinical trials. For patients who enroll in a TIL clinical trial, the process begins with a tumor biopsy. That biopsy is then taken to a clinical laboratory, such as our Cell Therapy Manufacturing Facility, to isolate the TILs.
Tumor-Infiltrating Lymphocytes (TIL) Market Key Facts
-
According to the American Cancer Society, about 97,610 new melanomas will be diagnosed in the US in 2023. Out of the total number of cases, around 58,120 cases will be diagnosed in men and 39,490 cases in women.
-
According to ASCO, an estimated 236,740 adults (117,910 men and 118,830 women) in the United States were diagnosed with lung cancer in 2022.
-
As per Cancer Research UK, there are around 16,700 new melanoma skin cancer cases in the UK every year. Melanoma skin cancer is the 5th most common cancer in the UK, accounting for 4% of all new cancer cases in the UK. Incidence rates for melanoma skin cancer in the UK are highest in people aged 85 to 89.
-
According to SEER, it is estimated that there were around 62,210 cases of pancreatic cancer in the US, in 2022. These cases made up about 3.2% of all new cancer cases in the United States
-
As per Cancer Research UK, there are around 12,400 new head and neck cancer cases in the UK every year. Head and neck cancer is the 8th most common cancer in the UK, accounting for 3% of all new cancer cases. Incidence rates for head and neck cancer in the UK are highest in people aged 70 to 74.
-
According to the Global Cancer Observatory, the incidence cases of melanoma in France were 16,449 in 2020. These cases are expected to increase in the upcoming years.
Tumor-Infiltrating Lymphocytes (TIL) Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Tumor-Infiltrating Lymphocytes pipeline therapies. It also thoroughly assesses the Tumor-Infiltrating Lymphocytes market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the market trend for each marketed Tumor-Infiltrating Lymphocytes drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Tumor-Infiltrating Lymphocytes (TIL) Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Tumor-Infiltrating Lymphocytes epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Tumor-Infiltrating Lymphocytes epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Tumor-Infiltrating Lymphocytes (TIL) Epidemiology, Segmented as –
-
Total Cases of Solid Tumors in the 7MM (2019–2032) (e.g. Metastatic Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck, and others)
-
Patients on TIL therapies in the 7MM (2019–2032)
-
Treatable cases by Line of therapies in the 7MM (2019–2032)
Tumor-Infiltrating Lymphocytes (TIL) Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Tumor-Infiltrating Lymphocytes market or expected to be launched during the study period. The analysis covers the Tumor-Infiltrating Lymphocytes market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Tumor-Infiltrating Lymphocytes drugs based on their sale and market share.
The report also covers the Tumor-Infiltrating Lymphocytes pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Tumor-Infiltrating Lymphocytes companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Tumor-Infiltrating Lymphocytes Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/tumor-infiltrating-lymphocytes-market
Tumor-Infiltrating Lymphocytes (TIL) Therapeutics Analysis
Over the past decade, cell-based immunotherapy has become a powerful strategy in solid cancer therapy. Tumor-infiltrating lymphocytes (TILs) are a group of intratumoral lymphocytes. With the development of new technologies, the isolation and generation of TILs from tumor tissues have improved.
Recent clinical studies demonstrated that adopting cell transfer of tumor-infiltrating lymphocytes (TILs) for advanced solid tumors showed good efficacy. TIL therapy is a type of cell-based immunotherapy using the patient’s own immune cells from the microenvironment of the solid tumor to kill tumor cells.
Tumor-infiltrating lymphocyte (TIL) therapy has been investigated as a treatment modality for melanoma for almost 20 years. As an autologous cell therapy, manufacturing the infusion product is a highly specialized process involving tumor harvest and the extraction and large-scale ex vivo expansion of TILs.
Emerging and Marketed Tumor-Infiltrating Lymphocytes (TIL) Therapies Covered in the Report Include:
-
Lifileucel (LN-144) is an autologous Tumor Infiltrating Lymphocytes (TIL) cell therapy that utilizes a 22-day centralized GMP process for the treatment of patients with advanced melanoma. Previously in August 2022, a rolling submission of the BLA for lifileucel was initiated to the FDA based on findings of the phase 2 C-144-01 trial) which assessed the efficacy and safety of the TIL therapy lifileucel in this patient population.
-
IOV-4001 is another investigational drug developed by Iovance Biotherapeutics. In 2022, the company announced that it has dosed the first participant and completed the safety observation period in the Phase I/II IOV-GM1-201 trial of IOV-4001, a genetically modified, tumor-infiltrating lymphocyte (TIL) therapy.
Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @
https://www.delveinsight.com/sample-request/tumor-infiltrating-lymphocytes-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Tumor-Infiltrating Lymphocytes Competitive Intelligence Analysis
4. Tumor-Infiltrating Lymphocytes Market Overview at a Glance
5. Tumor-Infiltrating Lymphocytes Disease Background and Overview
6. Tumor-Infiltrating Lymphocytes Patient Journey
7. Tumor-Infiltrating Lymphocytes Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Tumor-Infiltrating Lymphocytes Treatment Algorithm, Current Treatment, and Medical Practices
9. Tumor-Infiltrating Lymphocytes Unmet Needs
10. Key Endpoints of Tumor-Infiltrating Lymphocytes Treatment
11. Tumor-Infiltrating Lymphocytes Marketed Therapies
12. Tumor-Infiltrating Lymphocytes Emerging Drugs and Latest Therapeutic Advances
13. Tumor-Infiltrating Lymphocytes Seven Major Market Analysis
14. Attribute Analysis
15. Tumor-Infiltrating Lymphocytes Market Outlook (In US, EU5, and Japan)
16. Tumor-Infiltrating Lymphocytes Companies Active in the Market
17. Tumor-Infiltrating Lymphocytes Access and Reimbursement Overview
18. KOL Views on the Tumor-Infiltrating Lymphocytes Market
19. Tumor-Infiltrating Lymphocytes Market Drivers
20. Tumor-Infiltrating Lymphocytes Market Barriers
21. Appendix
22. DelveInsight Capabilities
23. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Request the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/tumor-infiltrating-lymphocytes-market
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
DelveInsight’s specialized oncology consulting empowers the pharma and biotech giants with tailored guidance and forefront proficiency, enabling adept navigation of ever-evolving clinical, commercial, and regulatory landscapes. Explore further at @ Oncology Consulting Services
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/medical-devices